Amphastar Pharma (AMPH) Tops Q2 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Amphastar Pharmaceuticals (AMPH) PT Lowered to $19 at Jefferies Following Strong 2Q
August 11, 2017 8:22 AM EDTJefferies lowered its price target on Amphastar Pharmaceuticals (NASDAQ: AMPH) to $19.00 (from $20.00) while maintaining a Buy rating following the company's 2Q. AMPH reported EPS of $0.11, exceeding estimates by $0.07 driven by a topline of ~$65M, which topped forecasts by $5.2M.
Management appears more... More
